This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Researchers To Present New Data On Soliris® (eculizumab) As A Treatment For Patients With AHUS At ASN Annual Meeting

Abstract [SA-PO852]: “Eculizumab Maintains Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 3-Year Update,” Gaber, et al.

Accessible at: http://www.abstracts2view.com/asn_2013/view.php?nu=5311&terms=&type=abstract

Abstract [SA-PO850]: “Eculizumab in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): Sustained Efficacy at 3 Years,” Delmas, et al.

Accessible at: http://www.abstracts2view.com/asn_2013/view.php?nu=5506&terms=&type=abstract

Abstract [SA-PO849]: “Eculizumab Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function in Pediatric Atypical Hemolytic Uremic Syndrome (aHUS) Patients,” Greenbaum, et al.

Accessible at: http://www.abstracts2view.com/asn_2013/view.php?nu=5579&terms=&type=abstract

Abstract [SA-PO853]: “An Observational, Non-Interventional, Multicenter, Multinational Registry of Patients with Atypical Hemolytic Uremic Syndrome (aHUS): Initial Patient Characteristics,” Licht, et al.

Accessible at: http://www.abstracts2view.com/asn_2013/view.php?nu=5184&terms=&type=abstract

About Soliris

Soliris is a first-in-class terminal complement inhibitor developed from the laboratory through regulatory approval and commercialization by Alexion. Soliris is also approved in the US, European Union, Japan and other countries as the first and only treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder, characterized by complement-mediated hemolysis (destruction of red blood cells).

Soliris is also approved in the US, the European Union, Japan and other countries as the first and only treatment for patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, a debilitating, ultra-rare and life-threatening genetic disorder characterized by complement-mediated thrombotic microangiopathy (blood clots in small vessels). The effectiveness of Soliris in aHUS is based on the effects on thrombotic microangiopathy (TMA) and renal function. Prospective clinical trials in additional patients are ongoing to confirm the benefit of Soliris in patients with aHUS. Soliris is not indicated for the treatment of patients with Shiga-toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Alexion's breakthrough approach in complement inhibition has received the pharmaceutical industry's highest honors: the 2008 Prix Galien USA Award for Best Biotechnology Product with broad implications for future biomedical research and the 2009 Prix Galien France Award in the category of Drugs for Rare Diseases.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs